Johnson & Johnson (JNJ)vsMarker Therapeutics Inc (MRKR)
JNJ
Johnson & Johnson
$266.38
+0.30%
HEALTHCARE · Cap: $640.02B
MRKR
Marker Therapeutics Inc
$1.15
-4.17%
HEALTHCARE · Cap: $20.67M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 2761030% more annual revenue ($97.93B vs $3.55M). JNJ leads profitability with a 21.5% profit margin vs -245.5%. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
MRKR
Avoid22
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-88.9%
Fair Value
$140.57
Current Price
$266.38
$125.81 premium
Intrinsic value data unavailable for MRKR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Expensive relative to growth rate
Earnings declined 0.9%
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -77.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bull Case : MRKR
The strongest argument for MRKR centers on Price/Book.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : MRKR
The primary concerns for MRKR are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
JNJ profiles as a mature stock while MRKR is a turnaround play — different risk/reward profiles.
MRKR carries more volatility with a beta of 1.51 — expect wider price swings.
JNJ is growing revenue faster at 6.6% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 22/100), backed by strong 21.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Marker Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based immunotherapies and peptide-based vaccines for the treatment of hematologic malignancies and solid tumor indications. The company is headquartered in Houston, Texas.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?